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CORRESPONDENCE
Major Infection During Methotrexate 
Treatment for Rheumatoid Arthritis
Dear Sir:
We read with interest the article of Boer- 
booms et al in the June 1995 issue of Seminars, 
who reported the frequency of infection in 
rheumatoid arthritis (RA) patients being treated 
with m ethotrexate (MTX) or azathioprine 
(AZA ) .1 In a comparative study of 31 and 33 
patients treated with MTX and AZA, respec­
tively, and in an open, prospective study of 16 
MTX-treated patients, the authors found no 
difference in the rate of infection between the 
two treatment modalities, no opportunistic infec­
tions other than herpes zoster, and no associa­
tion of infection with concomitant corticoste­
roid treatment. We feel impelled to relate their 
results to the data of our prospective study of 
the long-term tolerability of MTX in RA, which, 
on the basis of a much larger number of pa­
tients, strengthen some, but not all, of their 
conclusions.2
In our study, 185 consecutive patients with 
RA according to American Rheumatoid Asso­
ciation criteria were recruited from the inpa­
tient pool of a single clinical department.3 This 
department is a referral center for rheumatic 
diseases, and the cohort was thus characterized 
by a high rate of patients with severe disease. 
Patients were randomized to receive 15 or 25 
mg MTX/week initially. Adjustment of the 
MTX dose according to efficacy and tolerability 
resulted in mean doses of 16.8 ± 5.5 mg and 
19.7 ±  6.0 mg/week, respectively, after 12 
months and 17.6 ± 6.2 mg and 18.5 ± 6.9 mg/wk 
at month 30. For the purpose of this analysis, 
the two groups were pooled. This resulted in 
168 patients eligible for evaluation during 
months 1 through 12 and 123 patients during 
months 13 through 30. Adverse events were 
registered during follow-up examinations on a 
regular basis by the patients’ local physicians in 
collaboration with the clinical department. Inter­
vals for monitoring were 2 weeks initially and 2 
to 4 weeks later. All episodes of bacterial 
infection severe enough to require antibiotic 
treatment, and of herpes zoster, were catego­
rized as major infections and registered. Nonexu­
dative pharyngitis and bronchitis are not consid­
ered to need antibiotic treatm ent in this country 
and thus were not registered.
A total of 65 episodes of major infection 
occurred in 56 patients during the follow-up 
period of 30 months (Table 1). Twenty episodes 
occurred during the first year and 45 during 
months 13 through 30. The lower respiratory 
tract was affected most frequently. Specifically, 
purulent bronchitis occurred in 16 instances 
and bacterial pneumonia in 9 instances. To­
gether with 6 episodes of purulent sinusitis and 
exudative angina, the upper and lower respira­
tory tracts accounted for 31 of 65 episodes 
(48%) of major infection. Urinary tract infec­
tions necessitating antibiotic treatm ent ac­
counted for 25% of total infections and were 
second in frequency only to respiratory tract 
infections. Purulent skin infections were less 
frequent, and cholecystitis, febrile enteritis, and 
wound infection after hip joint replacem ent 
were only observed in isolated cases. Herpes 
zoster developed in five patients, but no other 
opportunistic infections were seen.
The mean dose of MTX at the time of 
infection was 18.7 ±  6.9 mg/wk, which did not 
differ significantly from the respective figure in 
the entire cohort. Twenty-nine of the 65 epi­
sodes (45%) occurred during concomitant meth- 
ylprednisolone treatment, the median dose be­
ing 4 mg/day. W hen all infections were 
combined, the percentage of patients on cortico­
steroid and the median dose of corticosteroid in 
the patients with infections did not differ signifi­
cantly from the respective figures in the entire 
cohort.
Four deaths occurred during the study, with 
infections being implicated as causative. The 
age of these patients was 64, 69, 81, and 84 
years; all had severe, long-standing R A  (ARA 
class III to IV). One patient died of bacterial 
sepsis during apparently MTX-induced pancyto­
penia. Although no risk factors for MTX toxic­
ity were apparent in this patient, there is little 
doubt that MTX-induced toxicity played a deci­
sive role in this patient’s death. In the remaining 
three patients, leukocytes were within the nor-
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Table 1: Number of Bacterial Infections 
Necessitating Antibiotic Treatment, and of 
Herpes Zoster lnfectionsr During Methotrexate
Treatment
mal range at the time of demise. Two patients 
died of bronchopneumonia together with con­
gestive heart failure resuJting from mitral incom­
petence in one and coronary heart disease in 
the other. The fourth patient became bedridden 
because of Parkinson’s disease and developed 
recurrent and eventually lethal sepsis caused by 
decubital ulcers. Thus the last three patients 
had a condition that by itself would provide 
a plausible explanation for the lethal outcome, 
although a contributory role for MTX cannot be 
excluded.
These data support three main findings of the 
study of Boerbooms et al.1 First, the respiratory 
tract was the organ system most frequently 
affected. This calls for heightened vigilance for 
infection at this site in RA  patients receiving 
MTX and causes us to seek alternative second- 
line treatm ent in patients at increased risk for 
respiratory tract infection, eg, severe chronic 
bronchitis, bronchiectasis, or chronic left heart 
failure. Second, the percentage of patients re­
ceiving concomitant corticosteroid medication 
and the median corticosteroid dose were no 
higher in patients with infection than in patients 
without. This tends to support the conclusion of 
Boerbooms et al that less than 10 mg predniso­
lone equivalent does not have a major effect on 
susceptibility to infection, although the number 
of patients in the two studies may be too small
to detect a minor effect. Third, no opportunistic 
infections other than herpes zoster were ob­
served in these patients. This confirms the 
notion that conventional pathogens are the 
main problem during M TX treatm ent, although 
available studies may be too small to detect a 
minor effect.
In contrast to the findings of Boerbooms et al, 
the rate of infections did not cluster in the 
initial phase of MTX treatm ent in our study but 
was essentially stable over time. W e cannot, 
therefore, support the conclusion that the first 
year of MTX treatm ent is a particularly vulner­
able phase in this regard.
Taken together, the current data and previ­
ous studies provide a reasonably clear picture of 
the spectrum of major infection that may be 
encountered in RA  patients receiving MTX 
trea tm en t1’2*4 The respiratory tract is the most 
common site of infection in this setting, fol­
lowed by urinary tract and soft tissue infections. 
Because of the lack of a control group, the 
current study does not answer the question 
whether MTX increases the risk of infection in 
RA. The study of Boerbooms et al presents 
evidence against a previous, nonrandomized 
retrospective analysis that suggested that MTX 
treatm ent is associated with a higher rate of 
infection than treatm ent with other second-line 
agents.5 Conversely, a prospective case-control 
study showed a significantly higher rate of 
infection in M TX-treated RA patients as com­
pared with patients receiving other second-line 
agents.4 It remains unresolved as to what extent 
the condition being treated contributed to the 
inconsistent results. Because severe R A  is asso­
ciated with a higher rate of infection , 1’6 further 
study of this issue should be carefully controlled 
for disease severity and take into account the 
possibility that the effect of M TX on susceptibil­
ity to infection may vary with disease severity.
On the basis of the current evidence, we 
postulate that severe R A  under treatm ent with 
MTX be considered a risk for major infection. 
Although the optimal management remains a 
m atter of clinical judgment, a case can be made 
for prompt and vigorous anti-infectious treat­
ment in this setting and for restricting the use of 
MTX in RA patients with concomitant condi­
Months 1-12 Months 13-30
(total no./no. with 
corticosteroids)
Purulent bronchitis 5/1 11/3
Bacterial pneumonia 4/4 5/3
Purulent sinusitis or
pharyngitis 3/0 3/1
Urinary tract infection 4/0 12/6
Purulent skin infection 2/2 6/3
Cholecystitis 0 2/1
Febrile enteritis 2/1 0
Surgical wound infec­
tion 0 1/1
Herpes zoster 0 5/3
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tions that may confer an increased susceptibility 
to infection.
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Reply. We read with interest the comment by 
Schnabel et al. They describe their open prospec­
tive study on patients with rheumatoid arthritis 
(RA) treated with methotrexate (M TX ) .1 There 
are two main differences between their study 
and ours,2 First the dose of MTX in the open 
prospective study of Schnabel was 18.7 mg ± 6.9 
mg/week at the time of infection, which did not 
differ significantly from the respective figure in 
the entire cohort. In our studies the dose of
MTX was considerably lower, ie, 5 to 15 mg/ 
week. Second, the follow-up period in the study 
of Schnabel was 13 to 30 months for 123 
patients. O ur follow-up for the patients in the 
open prospective study was 72 months, whereas 
the 12  months randomized double blind trial 
was followed by a 36-month open prospective 
evaluation.
In contrast to our finding, that the most 
vulnerable phase for developing infection dur­
ing MTX treatm ent in R A  is the first year of 
treatment, Schnabel found that the rate of 
infection did not cluster in the initial phase of 
MTX treatm ent. This may relate to the above- 
mentioned differences between the studies. In 
this context it might be of interest to mention 
that reviewing 24 relevant papers on the issue 
indicated that most infections occur in the first
1 Vi years of MTX treatment.
Finally, Schnabel commented that we suggest 
that MTX treatm ent is not associated with a 
higher rate of infection than treatm ent with 
other second-line agents.2’3 We would like to 
stress that we only have reported the compari­
son between MTX and A Z A .2
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